Aerpio Pharmaceuticals is a biopharmaceutical company that is focused on developing compounds to treat ocular diseases and diabetic complications by activating Tie2. The company's lead compound, razuprotafib, is a first-in-class small molecule inhibitor that is being developed as a potential treatment for open angle glaucoma, and the company is also evaluating development options for its humanized monoclonal antibody, ARP-1536, for diabetic vascular complications. Additionally, the company has a bispecific antibody that has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. The company has exclusively out-licensed AKB-4924 to Gossamer Bio, which is being developed by its exclusive licensor. Recently published mouse and human genetic data further supports the therapeutic potential of Tie2 activation for treating ocular diseases and diabetic complications.
Aerpio Pharmaceuticals, Inc.'s ticker is ARPO
The company's shares trade on the NASDAQ stock exchange
They are based in Cincinnati, Ohio
There are 11-50 employees working at Aerpio Pharmaceuticals, Inc.
It is https://aerpio.com/
Aerpio Pharmaceuticals, Inc. is in the Healthcare sector
Aerpio Pharmaceuticals, Inc. is in the Biotechnology industry
The following five companies are Aerpio Pharmaceuticals, Inc.'s industry peers: